Ptc Therapeutics, INC Schedule 13G passive stakes

The Toronto-Dominion Bank has filed a Schedule 13G, reporting beneficial ownership of 3,025,945 shares, or 3.7%, of PTC Therapeutics, Inc. common stock as of March 31, 2026.

Janus Henderson Group plc has reported beneficial ownership of 7,193,433 shares, representing 8.7% of the outstanding common stock of PTC Therapeutics, Inc., as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 5.17% of PTC Therapeutics Inc.'s common stock as of March 31, 2026.

Vanguard Portfolio Management has reported a beneficial ownership of 5.88% in PTC Therapeutics Inc., holding over 4.87 million shares.

The Vanguard Group has reported a 0% beneficial ownership in PTC Therapeutics Inc. following an internal realignment.

Janus Henderson Group plc has reported a 6.0% beneficial ownership stake in PTC Therapeutics, Inc. common stock.

The Toronto-Dominion Bank has reported a 5.2% beneficial ownership stake in PTC Therapeutics, Inc., holding 4,138,215 shares.

Wellington Management Group and its affiliates reported a 4.8% passive ownership stake in PTC Therapeutics, Inc. common stock.

State Street Corporation has reported a 5.2% beneficial ownership stake in PTC Therapeutics Inc. common stock as of December 31, 2025.

BlackRock, Inc. has filed an Amendment No. 12 to Schedule 13G, reporting a 14.8% beneficial ownership in PTC Therapeutics, Inc.'s common stock.

Armistice Capital, LLC and Steven Boyd have reported a 4.08% beneficial ownership stake in PTC Therapeutics, Inc. as of September 30, 2025.

The Vanguard Group has increased its beneficial ownership in PTC Therapeutics Inc. to 10.43% of common stock, holding 8,288,999 shares.

Armistice Capital and Steven Boyd report a 5.96% beneficial ownership stake in PTC Therapeutics, Inc. through an amended Schedule 13G filing.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a shared beneficial ownership of 5,434,843 shares, representing 6.86% of PTC Therapeutics, Inc.'s common stock.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a passive beneficial ownership of 8.0% in PTC Therapeutics, Inc.'s common stock as of March 31, 2025.

Armistice Capital, LLC and Steven Boyd have disclosed a passive beneficial ownership of 8.27% in PTC Therapeutics, Inc., totaling 6,378,000 shares of common stock as of December 31, 2024.

Camber Capital Management LP and Stephen DuBois have jointly disclosed a passive beneficial ownership of 4.15% in PTC Therapeutics, Inc., totaling 3.2 million shares as of December 31, 2024.

Wellington Management Group LLP and its affiliates have disclosed a beneficial ownership of 6.2% in PTC Therapeutics, Inc. common stock as of December 31, 2024.